FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117595314> ?p ?o ?g. }

• W2117595314 abstract "Foot ulcers are a major complication of diabetes mellitus, often leading to amputation. Growth factors derived from blood platelets, endothelium, or macrophages could potentially be an important treatment for these wounds but they may also confer risks.To assess the benefits and harms of growth factors for foot ulcers in patients with type 1 or type 2 diabetes mellitus.In March 2015 we searched the Cochrane Wounds Group Specialised Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), Ovid MEDLINE, Ovid MEDLINE (In-Process & Other Non-Indexed Citations, Ovid EMBASE and EBSCO CINAHL. There were no restrictions with respect to language, date of publication or study setting.Randomised clinical trials in any setting, recruiting people with type 1 or type 2 diabetes mellitus diagnosed with a foot ulcer. Trials were eligible for inclusion if they compared a growth factor plus standard care (e.g., antibiotic therapy, debridement, wound dressings) versus placebo or no growth factor plus standard care, or compared different growth factors against each other. We considered lower limb amputation (minimum of one toe), complete healing of the foot ulcer, and time to complete healing of the diabetic foot ulcer as the primary outcomes.Independently, we selected randomised clinical trials, assessed risk of bias, and extracted data in duplicate. We estimated risk ratios (RR) for dichotomous outcomes. We measured statistical heterogeneity using the I(2) statistic. We subjected our analyses to both fixed-effect and random-effects model analyses.We identified 28 randomised clinical trials involving 2365 participants. The cause of foot ulcer (neurologic, vascular, or combined) was poorly defined in all trials. The trials were conducted in ten countries. The trials assessed 11 growth factors in 30 comparisons: platelet-derived wound healing formula, autologous growth factor, allogeneic platelet-derived growth factor, transforming growth factor β2, arginine-glycine-aspartic acid peptide matrix, recombinant human platelet-derived growth factor (becaplermin), recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human vascular endothelial growth factor, recombinant human lactoferrin, and recombinant human acidic fibroblast growth factor. Topical intervention was the most frequent route of administration. All the trials were underpowered and had a high risk of bias. Pharmaceutical industry sponsored 50% of the trials.Any growth factor compared with placebo or no growth factor increased the number of participants with complete wound healing (345/657 (52.51%) versus 167/482 (34.64%); RR 1.51, 95% CI 1.31 to 1.73; I(2) = 51%, 12 trials; low quality evidence). The result is mainly based on platelet-derived wound healing formula (36/56 (64.28%) versus 7/27 (25.92%); RR 2.45, 95% 1.27 to 4.74; I(2) = 0%, two trials), and recombinant human platelet-derived growth factor (becaplermin) (205/428 (47.89%) versus 109/335 (32.53%); RR 1.47, 95% CI 1.23 to 1.76, I(2)= 74%, five trials).In terms of lower limb amputation (minimum of one toe), there was no clear evidence of a difference between any growth factor and placebo or no growth factor (19/150 (12.66%) versus 12/69 (17.39%); RR 0.74, 95% CI 0.39 to 1.39; I(2) = 0%, two trials; very low quality evidence). One trial involving 55 participants showed no clear evidence of a difference between recombinant human vascular endothelial growth factor and placebo in terms of ulcer-free days following treatment for diabetic foot ulcers (RR 0.64, 95% CI 0.14 to 2.94; P value 0.56, low quality of evidence)Although 11 trials reported time to complete healing of the foot ulcers in people with diabetes , meta-analysis was not possible for this outcome due to the unique comparisons within each trial, failure to report data, and high number of withdrawals. Data on quality of life were not reported. Growth factors showed an increasing risk of overall adverse event rate compared with compared with placebo or no growth factor (255/498 (51.20%) versus 169/332 (50.90%); RR 0.83; 95% CI 0.72 to 0.96; I(2) = 48%; eight trials; low quality evidence). Overall, safety data were poorly reported and adverse events may have been underestimated.This Cochrane systematic review analysed a heterogeneous group of trials that assessed 11 different growth factors for diabetic foot ulcers. We found evidence suggesting that growth factors may increase the likelihood that people will have complete healing of foot ulcers in people with diabetes. However, this conclusion is based on randomised clinical trials with high risk of systematic errors (bias). Assessment of the quality of the available evidence (GRADE) showed that further trials investigating the effect of growth factors are needed before firm conclusions can be drawn. The safety profiles of the growth factors are unclear. Future trials should be conducted according to SPIRIT statement and reported according to the CONSORT statement by independent investigators and using the Foundation of Patient-Centered Outcomes Research recommendations." @default.
• W2117595314 created "2016-06-24" @default.
• W2117595314 creator A5019275846 @default.
• W2117595314 creator A5020180402 @default.
• W2117595314 creator A5051753481 @default.
• W2117595314 creator A5054278670 @default.
• W2117595314 creator A5064953628 @default.
• W2117595314 creator A5083375783 @default.
• W2117595314 creator A5086681968 @default.
• W2117595314 date "2015-10-28" @default.
• W2117595314 modified "2023-10-09" @default.
• W2117595314 title "Growth factors for treating diabetic foot ulcers" @default.
• W2117595314 cites W137840232 @default.
• W2117595314 cites W1467566154 @default.
• W2117595314 cites W1564506745 @default.
• W2117595314 cites W1600560134 @default.
• W2117595314 cites W1601356608 @default.
• W2117595314 cites W1605841001 @default.
• W2117595314 cites W1649363101 @default.
• W2117595314 cites W1683372015 @default.
• W2117595314 cites W169577780 @default.
• W2117595314 cites W1713807336 @default.
• W2117595314 cites W1815191336 @default.
• W2117595314 cites W1815558303 @default.
• W2117595314 cites W1892066952 @default.
• W2117595314 cites W1898277237 @default.
• W2117595314 cites W1917083480 @default.
• W2117595314 cites W1949832432 @default.
• W2117595314 cites W1965676751 @default.
• W2117595314 cites W1966371840 @default.
• W2117595314 cites W1968392481 @default.
• W2117595314 cites W1968537899 @default.
• W2117595314 cites W1968561916 @default.
• W2117595314 cites W1971039621 @default.
• W2117595314 cites W1972260676 @default.
• W2117595314 cites W1972678673 @default.
• W2117595314 cites W1974328347 @default.
• W2117595314 cites W1974815381 @default.
• W2117595314 cites W1975755202 @default.
• W2117595314 cites W1978389001 @default.
• W2117595314 cites W1980913786 @default.
• W2117595314 cites W1981680557 @default.
• W2117595314 cites W1983079870 @default.
• W2117595314 cites W1984052453 @default.
• W2117595314 cites W1986360186 @default.
• W2117595314 cites W1987908917 @default.
• W2117595314 cites W1988091812 @default.
• W2117595314 cites W1988691104 @default.
• W2117595314 cites W1991165227 @default.
• W2117595314 cites W1992816102 @default.
• W2117595314 cites W1992907904 @default.
• W2117595314 cites W1993057463 @default.
• W2117595314 cites W1993842439 @default.
• W2117595314 cites W1998779317 @default.
• W2117595314 cites W2000245923 @default.
• W2117595314 cites W2000502072 @default.
• W2117595314 cites W2001429880 @default.
• W2117595314 cites W2003756366 @default.
• W2117595314 cites W2004755889 @default.
• W2117595314 cites W2008081982 @default.
• W2117595314 cites W2009326492 @default.
• W2117595314 cites W2009539511 @default.
• W2117595314 cites W2010028239 @default.
• W2117595314 cites W2010149513 @default.
• W2117595314 cites W2013883481 @default.
• W2117595314 cites W2014398076 @default.
• W2117595314 cites W2015610252 @default.
• W2117595314 cites W2018061190 @default.
• W2117595314 cites W2020234367 @default.
• W2117595314 cites W2025827754 @default.
• W2117595314 cites W2027464447 @default.
• W2117595314 cites W2027679013 @default.
• W2117595314 cites W2028631776 @default.
• W2117595314 cites W2029665042 @default.
• W2117595314 cites W2029874501 @default.
• W2117595314 cites W2032541700 @default.
• W2117595314 cites W2032589933 @default.
• W2117595314 cites W2033036174 @default.
• W2117595314 cites W2034960421 @default.
• W2117595314 cites W2037783399 @default.
• W2117595314 cites W2038630179 @default.
• W2117595314 cites W2039604933 @default.
• W2117595314 cites W2039788709 @default.
• W2117595314 cites W2041166247 @default.
• W2117595314 cites W2042269088 @default.
• W2117595314 cites W2044859490 @default.
• W2117595314 cites W2044942006 @default.
• W2117595314 cites W2046279374 @default.
• W2117595314 cites W2046391772 @default.
• W2117595314 cites W2047047942 @default.
• W2117595314 cites W2048627234 @default.
• W2117595314 cites W2049202495 @default.
• W2117595314 cites W2050405658 @default.
• W2117595314 cites W2052038646 @default.
• W2117595314 cites W2054934928 @default.
• W2117595314 cites W2055692369 @default.
• W2117595314 cites W2058365382 @default.
• W2117595314 cites W2058460635 @default.
• W2117595314 cites W2060113764 @default.
• W2117595314 cites W2069786094 @default.

• next